PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes

Pierre Jacques Hamard, Gabriel E. Santiago, Fan Liu, Daniel L. Karl, Concepcion Martinez, Na Man, Adnan K. Mookhtiar, Stephanie Duffort, Sarah Greenblatt, Ramiro E Verdun, Stephen D Nimer

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Protein arginine methyltransferase 5 (PRMT5) is overexpressed in many cancer types and is a promising therapeutic target for several of them, including leukemia and lymphoma. However, we and others have reported that PRMT5 is essential for normal physiology. This dependence may become dose limiting in a therapeutic setting, warranting the search for combinatorial approaches. Here, we report that PRMT5 depletion or inhibition impairs homologous recombination (HR) DNA repair, leading to DNA-damage accumulation, p53 activation, cell-cycle arrest, and cell death. PRMT5 symmetrically dimethylates histone and non-histone substrates, including several components of the RNA splicing machinery. We find that PRMT5 depletion or inhibition induces aberrant splicing of the multifunctional histone-modifying and DNA-repair factor TIP60/KAT5, which selectively affects its lysine acetyltransferase activity and leads to impaired HR. As HR deficiency sensitizes cells to PARP inhibitors, we demonstrate here that PRMT5 and PARP inhibitors have synergistic effects on acute myeloid leukemia cells. Hamard et al. show that PRMT5 regulates DNA-repair efficiency in hematopoietic cells by controlling the alternative splicing of key histone modifying and DNA-repair proteins, including TIP60. PRMT5 depletion or inhibition leads to a defect in DNA-repair pathway choice, which may be exploited therapeutically to target acute leukemia cells.

Original languageEnglish (US)
Pages (from-to)2643-2657
Number of pages15
JournalCell Reports
Volume24
Issue number10
DOIs
StatePublished - Sep 4 2018

Fingerprint

Protein-Arginine N-Methyltransferases
Alternative Splicing
DNA Repair
Histones
Repair
DNA
Enzymes
Homologous Recombination
Leukemia
RNA Splicing
Recombinational DNA Repair
Acetyltransferases
Physiology
Cell death
Myeloid Cells
Cell Cycle Checkpoints
Acute Myeloid Leukemia
Lysine
DNA Damage
Machinery

Keywords

  • 53BP1
  • acute myeloid leukemia
  • alternative splicing
  • DNA damage and repair
  • hematopoiesis
  • histone post-translational modifications acetylation
  • homologous recombination
  • methylation
  • PARP inhibitor
  • PRMT5
  • PRMT5 inhibitor
  • Tip60/KAT5

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. / Hamard, Pierre Jacques; Santiago, Gabriel E.; Liu, Fan; Karl, Daniel L.; Martinez, Concepcion; Man, Na; Mookhtiar, Adnan K.; Duffort, Stephanie; Greenblatt, Sarah; Verdun, Ramiro E; Nimer, Stephen D.

In: Cell Reports, Vol. 24, No. 10, 04.09.2018, p. 2643-2657.

Research output: Contribution to journalArticle

Hamard, PJ, Santiago, GE, Liu, F, Karl, DL, Martinez, C, Man, N, Mookhtiar, AK, Duffort, S, Greenblatt, S, Verdun, RE & Nimer, SD 2018, 'PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes', Cell Reports, vol. 24, no. 10, pp. 2643-2657. https://doi.org/10.1016/j.celrep.2018.08.002
Hamard, Pierre Jacques ; Santiago, Gabriel E. ; Liu, Fan ; Karl, Daniel L. ; Martinez, Concepcion ; Man, Na ; Mookhtiar, Adnan K. ; Duffort, Stephanie ; Greenblatt, Sarah ; Verdun, Ramiro E ; Nimer, Stephen D. / PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes. In: Cell Reports. 2018 ; Vol. 24, No. 10. pp. 2643-2657.
@article{8547d686519546858495952706ce0bf8,
title = "PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes",
abstract = "Protein arginine methyltransferase 5 (PRMT5) is overexpressed in many cancer types and is a promising therapeutic target for several of them, including leukemia and lymphoma. However, we and others have reported that PRMT5 is essential for normal physiology. This dependence may become dose limiting in a therapeutic setting, warranting the search for combinatorial approaches. Here, we report that PRMT5 depletion or inhibition impairs homologous recombination (HR) DNA repair, leading to DNA-damage accumulation, p53 activation, cell-cycle arrest, and cell death. PRMT5 symmetrically dimethylates histone and non-histone substrates, including several components of the RNA splicing machinery. We find that PRMT5 depletion or inhibition induces aberrant splicing of the multifunctional histone-modifying and DNA-repair factor TIP60/KAT5, which selectively affects its lysine acetyltransferase activity and leads to impaired HR. As HR deficiency sensitizes cells to PARP inhibitors, we demonstrate here that PRMT5 and PARP inhibitors have synergistic effects on acute myeloid leukemia cells. Hamard et al. show that PRMT5 regulates DNA-repair efficiency in hematopoietic cells by controlling the alternative splicing of key histone modifying and DNA-repair proteins, including TIP60. PRMT5 depletion or inhibition leads to a defect in DNA-repair pathway choice, which may be exploited therapeutically to target acute leukemia cells.",
keywords = "53BP1, acute myeloid leukemia, alternative splicing, DNA damage and repair, hematopoiesis, histone post-translational modifications acetylation, homologous recombination, methylation, PARP inhibitor, PRMT5, PRMT5 inhibitor, Tip60/KAT5",
author = "Hamard, {Pierre Jacques} and Santiago, {Gabriel E.} and Fan Liu and Karl, {Daniel L.} and Concepcion Martinez and Na Man and Mookhtiar, {Adnan K.} and Stephanie Duffort and Sarah Greenblatt and Verdun, {Ramiro E} and Nimer, {Stephen D}",
year = "2018",
month = "9",
day = "4",
doi = "10.1016/j.celrep.2018.08.002",
language = "English (US)",
volume = "24",
pages = "2643--2657",
journal = "Cell Reports",
issn = "2211-1247",
publisher = "Cell Press",
number = "10",

}

TY - JOUR

T1 - PRMT5 Regulates DNA Repair by Controlling the Alternative Splicing of Histone-Modifying Enzymes

AU - Hamard, Pierre Jacques

AU - Santiago, Gabriel E.

AU - Liu, Fan

AU - Karl, Daniel L.

AU - Martinez, Concepcion

AU - Man, Na

AU - Mookhtiar, Adnan K.

AU - Duffort, Stephanie

AU - Greenblatt, Sarah

AU - Verdun, Ramiro E

AU - Nimer, Stephen D

PY - 2018/9/4

Y1 - 2018/9/4

N2 - Protein arginine methyltransferase 5 (PRMT5) is overexpressed in many cancer types and is a promising therapeutic target for several of them, including leukemia and lymphoma. However, we and others have reported that PRMT5 is essential for normal physiology. This dependence may become dose limiting in a therapeutic setting, warranting the search for combinatorial approaches. Here, we report that PRMT5 depletion or inhibition impairs homologous recombination (HR) DNA repair, leading to DNA-damage accumulation, p53 activation, cell-cycle arrest, and cell death. PRMT5 symmetrically dimethylates histone and non-histone substrates, including several components of the RNA splicing machinery. We find that PRMT5 depletion or inhibition induces aberrant splicing of the multifunctional histone-modifying and DNA-repair factor TIP60/KAT5, which selectively affects its lysine acetyltransferase activity and leads to impaired HR. As HR deficiency sensitizes cells to PARP inhibitors, we demonstrate here that PRMT5 and PARP inhibitors have synergistic effects on acute myeloid leukemia cells. Hamard et al. show that PRMT5 regulates DNA-repair efficiency in hematopoietic cells by controlling the alternative splicing of key histone modifying and DNA-repair proteins, including TIP60. PRMT5 depletion or inhibition leads to a defect in DNA-repair pathway choice, which may be exploited therapeutically to target acute leukemia cells.

AB - Protein arginine methyltransferase 5 (PRMT5) is overexpressed in many cancer types and is a promising therapeutic target for several of them, including leukemia and lymphoma. However, we and others have reported that PRMT5 is essential for normal physiology. This dependence may become dose limiting in a therapeutic setting, warranting the search for combinatorial approaches. Here, we report that PRMT5 depletion or inhibition impairs homologous recombination (HR) DNA repair, leading to DNA-damage accumulation, p53 activation, cell-cycle arrest, and cell death. PRMT5 symmetrically dimethylates histone and non-histone substrates, including several components of the RNA splicing machinery. We find that PRMT5 depletion or inhibition induces aberrant splicing of the multifunctional histone-modifying and DNA-repair factor TIP60/KAT5, which selectively affects its lysine acetyltransferase activity and leads to impaired HR. As HR deficiency sensitizes cells to PARP inhibitors, we demonstrate here that PRMT5 and PARP inhibitors have synergistic effects on acute myeloid leukemia cells. Hamard et al. show that PRMT5 regulates DNA-repair efficiency in hematopoietic cells by controlling the alternative splicing of key histone modifying and DNA-repair proteins, including TIP60. PRMT5 depletion or inhibition leads to a defect in DNA-repair pathway choice, which may be exploited therapeutically to target acute leukemia cells.

KW - 53BP1

KW - acute myeloid leukemia

KW - alternative splicing

KW - DNA damage and repair

KW - hematopoiesis

KW - histone post-translational modifications acetylation

KW - homologous recombination

KW - methylation

KW - PARP inhibitor

KW - PRMT5

KW - PRMT5 inhibitor

KW - Tip60/KAT5

UR - http://www.scopus.com/inward/record.url?scp=85052651970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052651970&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2018.08.002

DO - 10.1016/j.celrep.2018.08.002

M3 - Article

C2 - 30184499

AN - SCOPUS:85052651970

VL - 24

SP - 2643

EP - 2657

JO - Cell Reports

JF - Cell Reports

SN - 2211-1247

IS - 10

ER -